Display options
Share it on

Int J Clin Pharmacol Ther. 2016 Nov;54(11):847-855. doi: 10.5414/CP202782.

Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.

International journal of clinical pharmacology and therapeutics

Wolfgang Frenzel, Stefan Wietek, Tor-Einar Svae, Anette Debes, Daniel Svorc

PMID: 27719744 PMCID: PMC5095453 DOI: 10.5414/CP202782

Abstract

OBJECTIVE: To evaluate the tolerability and safety of Octagam® 5% and 10% across all indications, ages, and treatment regimens, using data from four non-interventional post-authorization safety studies (PASS); this analysis was performed following changes in the preparation of raw material used to manufacture Octagam.

METHODS: All four studies included in- and out-patients prescribed Octagam for treatment of their medical condition. Physicians used case report forms to document baseline demographics, Octagam treatment details, and data on the efficacy of Octagam, and recorded all adverse drug reactions (ADRs) and other safety data.

RESULTS: Altogether 21,780 infusions of Octagam in 2,397 patients were included in our analysis. The most frequent indication for Octagam was secondary immunodeficiencies (SID; n = 1,368, 11,348 infusions), followed by primary immunodeficiencies (PID; n = 363; 3,923 infusions). During the individual patient observation, 83% of SID and 67% of PID patients were free of any infection. In up to 85% of all investigator assessments, Octagam was rated to have a favorable effect. In autoimmune diseases, investigators assessed Octagam as being beneficial in 70% (immune thrombocytopenia) up to 100% (Guillain-Barré syndrome), depending on the indication. The majority of patients (92%) tolerated Octagam treatment without any ADR. The overall incidence of reported ADRs was 1.0% for all infusions. The majority of ADRs were considered non-serious (93%) and mild or moderate (87%) in severity. No unexpected ADR signal was detected.

CONCLUSIONS: This analysis demonstrates that the changes in the preparation of raw material used to manufacture Octagam did not affect the safety profile of Octagam® 5% and 10%.
 *At the time of study realization.

References

  1. Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S115-9 - PubMed
  2. Best Pract Res Clin Haematol. 2006;19(1):3-25 - PubMed
  3. Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):1038-47 - PubMed
  4. Curr Opin Neurol. 2000 Oct;13(5):575-82 - PubMed
  5. Pharmacol Ther. 2004 Jun;102(3):177-93 - PubMed
  6. Hematology. 2010 Oct;15(5):351-9 - PubMed
  7. Int J Clin Pharmacol Ther. 2015 Jan;53(1):21-31 - PubMed
  8. N Engl J Med. 1991 Jul 11;325(2):110-7 - PubMed
  9. Drug Saf. 2006;29(5):385-96 - PubMed
  10. Lancet. 1994 Apr 30;343(8905):1059-63 - PubMed
  11. Int Immunopharmacol. 2006 Apr;6(4):535-42 - PubMed
  12. Int Arch Allergy Immunol. 2005 Mar;136(3):217-29 - PubMed
  13. N Engl J Med. 1988 Oct 6;319(14):902-7 - PubMed
  14. N Engl J Med. 1990 Sep 13;323(11):705-12 - PubMed
  15. Int Immunopharmacol. 2014 Dec;23(2):442-6 - PubMed
  16. Clin Exp Immunol. 2003 Aug;133(2):247-51 - PubMed
  17. Drug Saf. 1999 Sep;21(3):171-85 - PubMed
  18. Clin Exp Immunol. 1996 May;104 Suppl 1:43-8 - PubMed
  19. J Clin Immunol. 2004 May;24(3):309-14 - PubMed
  20. Immunotherapy. 2015;7(7):753-63 - PubMed
  21. Pharmacotherapy. 2005 Nov;25(11 Pt 2):78S-84S - PubMed
  22. BioDrugs. 1998 Oct;10(4):265-73 - PubMed

Substances

MeSH terms

Publication Types